Compare eBay Inc (EBAY) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
eBay Inc vs TG Therapeutics Inc — how do they compare? eBay Inc trades at $102.34 (market cap $47.17B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: eBay Inc is far larger — about 6.2× TG Therapeutics Inc's market cap, and eBay Inc pays a 1.17% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EBAY | TGTX | |
|---|---|---|
Market Cap | $47.17B | $7.64B |
Volume | 5,186,418 | — |
Sector | Consumer Cyclical | Health |
52-Week High | $118.96 | $59.06 |
52-Week Low | $79.41 | $26.94 |
Enterprise Value | $51.00B | $7.84B |
Dividend Yield | 1.17% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EBAY trades at $102.23, down 5.09% amid reports GameStop may abandon its $56 billion takeover bid in favor of a partnership. The stock shows bearish technical signals with support near $104, while fundamentals remain solid with Q2 2026 earnings beating estimates and an 18.57% net income margin. Revenue growth is projected to reach $12.0 billion in 2026, though cash flow turned negative in 2025.
The outlook is mixed: strong execution and a potential partnership or buyout offer present upside, but withdrawal of the bid and insider selling pose near-term risks. Analyst consensus is a $119.31 price target with a buy rating, but investors face volatility from deal uncertainty and competitive pressures in e-commerce.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About eBay Inc
eBay Inc. is a global commerce company. The Company's platforms are designed to enable sellers worldwide to organize and offer their inventory for sale and buyers to find and buy it. eBay's items can be new or used, plain or luxurious, commonplace or rare, trendy or one-of-a-kind.
Read more on EBAY →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
